Levzer-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively antagonizes peripheral H1 receptors, thereby alleviating symptoms including sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, inhibits the cysteinyl leukotriene receptor, reducing bronchoconstriction, inflammation, and mucus production associated with allergic responses and asthma. The synergistic action of these agents provides comprehensive relief from both upper and lower respiratory allergic manifestations. Levzer-M is typically prescribed for patients who require enhanced symptom control beyond monotherapy with either agent. It is generally well-tolerated; however, common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment and those with a history of neuropsychiatric events. The tablet should be administered orally once daily, preferably in the evening, with or without food. Levzer-M should be used under medical supervision, and patients should be monitored for therapeutic efficacy and potential side effects throughout the treatment duration.